Eikon Therapeutics, Inc. (EIKN)

Eikon Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Net Income	-324.25	-243.81	-242
Depreciation & Amortization	18.87	15.01	11.43
Stock-Based Compensation	18.04	12.43	9.54
Other Adjustments	20.99	0.93	20.21
Changes in Accounts Payable	-3.81	2.95	0.24
Changes in Accrued Expenses	16.62	5.16	17.09
Changes in Other Operating Activities	65.03	72.54	-7.35
Operating Cash Flow	-188.52	-134.8	-190.85
Capital Expenditures	-46.74	-84.8	-28.51
Purchases of Investments	-444.1	-360.35	-804.74
Proceeds from Sale of Investments	309.5	596.5	970.2
Investing Cash Flow	-181.34	151.35	136.95
Issuance of Common Stock	1.9	0.24	0.4
Net Common Stock Issued (Repurchased)	1.9	0.24	0.4
Issuance of Preferred Stock	350.15	-	105.41
Net Preferred Stock Issued (Repurchased)	350.15	-	105.41
Financing Cash Flow	352.05	0.24	105.81
Net Cash Flow	-17.81	16.8	51.91
Free Cash Flow	-235.26	-219.6	-219.36
Free Cash Flow Per Share	-81.29	-87.16	-108.23
Levered Free Cash Flow	-283.68	-232.96	-249.11
Unlevered Free Cash Flow	-288.98	-249.49	-272.85

Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q